



ABB10010P0470US (OZ-50061)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application Of:

Lubisch et al.

Serial No.: 10/088,604

Filed: July 1, 2002

) Benzodiazepine Derivatives, the Production

) and Use Thereof

)

)

) Group Art Unit: 1614

)

) Examiner: Bruck Kifle

1614  
11  
10/25/03  
OCT 22 2003  
TECH CENTER 1600/2900  
RECEIVED

### RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents  
BOX RESPONSES NO-FEE  
Alexandria, Virginia 22313-1450

Sir:


In response to the Restriction Requirement dated September 23, 2003, Applicants elect Group II (compounds and uses of Formula (I) where A is C<sub>2</sub>) with traverse.

Applicants traverse this Restriction Requirement on the grounds that there is a "single structural element that is shared by all of the alternatives", i.e., the compounds are all benzodiazepine derivatives and they also have the same utility.

Reconsideration of this Restriction Requirement is respectfully requested.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER

  
Martin L. Katz, Reg. No. 25,011

Date: October 17, 2003

Citicorp Center  
500 West Madison Street  
Suite 3800  
Chicago, IL 60661  
(312) 876-1800



ABB10010P0470US (OZ-50761)

37 CFR 1.8  
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, as first class mail in an envelope addressed to Commissioner for Patents, Box No-Fee, Alexandria, Virginia 22313-1450 on October 17, 2003.

Rebecca J. Willis